Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 35Uveal Melanoma 9Prostatic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Skin Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Lung Neoplasms 1Leukemia 1Fallopian Tube Neoplasms 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × incomplete Freund's adjuvant × Clear all
NCT00640861 2018-10-31

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Mayo Clinic

Phase EARLY_PHASE1 Completed
45 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡